Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy

Prostate Cancer Clinical Trial

Official title:

Influence of Androgen Suppression Therapy for Prostate Cancer on the Timing and Onset of Fatal Myocardial Infarctions in Men Undergoing Prostate Brachytherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00651222
• Other study ID #: MI-PB
• Status: Completed
• Phase: N/A
• First received: March 31, 2008
• Last updated: March 31, 2008

Study information

• Verified date: March 2008
• Source: Prostate Cancer Foundation of Chicago
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to review cause of death in patients undergoing prostate brachytherapy at a single institution. Furthermore, we are analyzing patients undergoing androgen deprivation therapy and whether or not this contributed to cardiovascular deaths, specifically myocardial infarction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Deceased anytime after prostate brachytherapy treatment

Exclusion Criteria:

• Patients whose cause of death was unable to be determined

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Cardiovascular Death
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Other:
• No intervention was required
Death records were reviewed, therefore, there was no intervention

Locations

Country	Name	City	State
United States	Chicago Prostate Center	Westmont	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Prostate Cancer Foundation of Chicago

Country where clinical trial is conducted

United States,